Hämostaseologische und molekulare Diagnostik des Von-Willebrand-Syndroms

R. Schneppenheim

doi:10.1055/s-0038-1660359

Hämostaseologie, Table of Contents

Hamostaseologie 1994; 14(04): 159-168
DOI: 10.1055/s-0038-1660359

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Hämostaseologische und molekulare Diagnostik des Von-Willebrand-Syndroms

R. Schneppenheim

¹Klinik für Allgemeine Pädiatrie im Klinikum der Christian-Albrechts-Universität Kiel (Direktor: Prof. Dr. med. J. Schaub)

› Author Affiliations

Abstract

Zusammenfassung

Seit der Erstbeschreibung des Von-Willebrand-Syndroms (vWS) als »Hereditär Pseudohemofili« durch Erik Adolf von Willebrand 1926 schaffte erst die Verfügbarkeit moderner hämostaseologischer und in letzter Zeit auch molekularer Methoden die Voraussetzung für die heutigen Kenntnisse über die Genetik und die Natur der zugrundeliegenden quantitativen, funktionellen und molekularen Defekte. Die bekannte ausgeprägte Heterogenität der klinischen Symptome und der Laborparameter korrespondiert mit der Natur und der Lokalisation der molekularen Defekte in definierten Regionen des multifunktionellen Von-Willebrand-Faktors. Das diagnostische Vorgehen und die Indikationen für zusätzliche molekulargenetische Untersuchungen zur Charakterisierung der verschiedenen heute bekannten Typen und Subtypen des vWS werden dargestellt.

Schlüsselwörter

Von-Willebrand-Syndrom - Von-Willebrand-Faktor - Diagnose - Genetik - molekulare Defekte

Full Text

References

LITERATUR
1 Anvret M, Blombäck M, Lindstedt M, Söderlind E, Tapper-Persson M, Thelander AC. Genetic and blood coagulation characterization of “Swedish” families with von Willebrand’s disease types I and III: New aspects of heredity. Hum Genet 1992; 89: 147-54.
2 Bahnak BR, Lavergne JM, Rothschild C, Meyer D. A stop codon in a patient with severe type III von Willebrand disease (letter). Blood 1991; 78: 1148-9.
3 Bird AP. DNA méthylation and the frequency of CpG in animal DNA. Nucleic Acids Res 1980; 08: 1499-504.
4 Bloom AL, Giddings JC, Wilks CJ. Factor VIII on the vascular intima: Possible importance in haemostasis and thrombosis. Nature New Biology 1973; 241: 217-9.
5 Bonthron D, Orr EC, Mitsock LM, Ginsburg D, Handin RI, Orkin SH. Nucleotide sequence of pre-pro-von Willebrand factor cDNA. Nucleic Acids Res 1986; 14: 7125-7.
6 Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
7 Budde U, Müller N, Hammerstein U, Lüchters G. Vorkommen milder Formen des von Willebrand-Syndroms Typ I in der »Normalbevölkerung«. In: Hämostase, Thrombophilie und Arteriosklerose. De Loo J v, Asbeck F. (Hrsg). Stuttgart: Schattauer; 1982: 505-10.
8 Eikenboom JCJ, Ploos HKvan Amstel, Reitsma PH, Briet E. Mutations in severe, type III von Willebrand’s disease in the Dutch population: candidate missense and nonsense mutations associated with reduced levels of von Willebrand factor messenger RNA. Thromb Haemostas 1992; 68: 448-54.
9 Eriksson AW, Hiepler E, Jürgens R, Lehmann W, Schulz H. Untersuchungen zur Thrombopathie (v. Willebrand-Jürgens). Klin Wochenschr 1961; 39: 32-42.
10 Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlsson BMWilhelm, Chavin SI, Abraham GN, Handin RI, Orkin SH. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Sciene 1986; 232: 995-8.
11 Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-6.
12 Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest 1985; 76: 1491-500.
13 Fulcher CA, Zimmerman TS. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody. Proc Natl Acad Sci USA 1982; 79: 1648-52.
14 Furlan M. Factor VIII/von Willebrand factor: a multivalent ligand binding to platelets and collagen. Blut 1986; 52: 329-36.
15 Ginsburg D, Bowie EJW. Molecular genetics of von Willebrand disease. Blood 1992; 79: 2507-19.
16 Ginsburg D, Handin RI, Bonthron DT, Donlon TA, Bruns GA, Latt SA, Orkin SH. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985; 228: 1401-6.
17 Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 177-84.
18 Girma JP, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationship of human von Willebrand factor. Blood 1987; 70: 605-11.
19 Hach-Wunderle V, Vigh Z, Scharrer I. Diagnostik und Therapie des von WillebrandSyndroms. Med Welt 1987; 38: 1654-7.
20 Holmberg L, Dent JA, Schneppenheim R, Budde U, Ware J, Ruggeri ZM. Von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure. J Clin Invest. 1993 in press..
21 Holmberg L, Nilsson IM. Von Willebrand disease. Clin Haematol 1985; 14: 461-88.
22 Hoyer LW, Los Santos RPD, Hoyer JR. Antihemophilic factor antigen. Localization in endothelial cells by immunofluorescent microscopy. J Clin Invest 1973; 52: 2737-44.
23 Hoyer LW, Shainoff JR. Factor VUI-related protein circulates in normal plasma as high molecular weight multimers. Blood 1980; 57: 1056-9.
24 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71: 1906-9.
25 Koutts J, Walsh PN, Plow EF, Fenton JW, Bouma BN, Zimmerman TS. Active release of human platelet factor VUI-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest 1978; 62: 1255-63.
26 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 124 (Suppl): 21-37.
27 Lenk H, Nilsson IM, Holmberg L, Weissbach G. Frequency of different types of von Willebrand’s disease in the GDR. Acta Med Scand 1988; 224: 275-80.
28 Loesberg C, Gonsalves MD, Zandbergen J, Willems C, von Aken WG, Stel HV, Van Mourik JA, De Groot PG. The effect of calcium on the secretion of factor VUI-related antigen by cultured human endothelial cells. Biochim Biophys Acta 1983; 763: 160-8.
29 Lynch DC, Williams R, Zimmerman TS, Kirby EP, Livingston DM. Biosynthesis of the subunits of factor VIIIR by bovine aortic endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2738-42.
30 Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. Letter: A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8.
31 Mancuso DJ, Tuley EA, Westfield LA, Worrall NK, Shelton BBInloes, Sorace JM, Alevy YG, Sadler JE. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-27.
32 Mancuso DJ, Tuley EA, Westfield LA, Lester TLMancuso, Le Beau MM, Sorace JM, Sadler JE. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991; 30: 253-69.
33 Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand’s disease in western Europe and Israel. Br J Haematol 1984; 57: 163-9.
34 Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA 1992; 89: 3531-5.
35 Mazurier C, Parquet AGernez, Goudemand M. Enzyme-linked immunoabsorbent assay of factor VUI-related antigen. Interest in study of Von Willebrand’s disease. Pathol Biol Paris 1977; 25: 18-24.
36 Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost 1992; 67: 391-6.
37 Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand’s disease. I. Phenotypic variation within families. Blood 1979; 54: 117-36.
38 Miller CH, Lenzi R, Breen C. Prevalence of von Willebrand’s disease among U.S. adults. Blood 1987; 70: 377a.
39 Mohri H, Zimmerman TS, Ruggeri ZM. Synthetic peptides inhibit the interaction of von Willebrand factor-platelet membrane glycoproteins. Peptides 1993; 14: 125-9.
40 Myers RM, Lumelsky N, Lerman LS, Maniatis T. Detection of single base substitutions in total genomic DNA. Nature 1985; 313: 495-8.
41 Nachman RL, Jaffe EA. Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med 1975; 141: 1101-13.
42 Ngo KY, Glotz VT, Koziol JA, Lynch DC, Gitschier J, Ranieri P, Ciavarella N, Ruggeri ZM, Zimmerman TS. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-7.
43 Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766-70.
44 Peake IR, Liddell MB, Moodie P, Standen G, Mancuso DJ, Tuley EA, Westfield LA, Sorace JM, Sadler JE, Verweij CL, Bloom AL. Severe type III von Willebrand’s disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood 1990; 75: 654-61.
45 Rand JH, Sussman II, Gordon RE, Chu SV, Solomon V. Localization of factor-VIII-related antigen in human vascular subendothelium. Blood 1980; 55: 752-6.
46 Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB - Candidate mutations cluster in one disulfide loop be-tween proposed platelet Glycoprotein IB binding sequences. J Clin Invest 1991; 87: 1220-6.
47 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-9.
48 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-25.
49 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/ von Willebrand factor. Blood 1981; 57: 1140-3.
50 Ruggeri ZM. Classification of von Willebrand disease. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen R, Arnout J. (Hrsg). Leuven: Leuven University Press; 1987: 419-45.
51 Ruggeri ZM, Zimmerman TS. von Willebrand factor and von Willebrand disease [published erratum appears in Blood 71 (3), 830 (1988)]. Blood 1987; 70: 895-904.
52 Sadler JE, Ginsburg D. A database of polymorphisms in the von Willebrand factor gene and pseudogene. For the Consortium on von Willebrand Factor Mutations and Polymorphisms and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 69: 185-91.
53 Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994; 71: 520-5.
54 Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-91.
55 Sakariassen KS, Nievelstein PF, Coller BS, Sixma JJ. The role of platelet membrane glycoproteins lb and Ilb-IIIa in platelet adherence to human artery subendothelium. Br J Haematol 1986; 63: 681-91.
56 Santoro SA. Adsorption of von Willebrand factor/factor VIII by the genetically distinct interstitial collagens. Thromb Res 1981; 21: 689-91.
57 Schneppenheim R, Plendl H, Budde U. Luminograph - an alternative assay for detection of von Willebrand factor multimers. Thromb Haemost 1988; 60: 133-6.
58 Schneppenheim R, Krey S, Bergmann F, Bock D, Budde U, Lange M, Linde R, Mittler U, Meili GE Mertes, Olek K, Plendl H, Simeoni E. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet. 1994 in press..
59 Shelton BBInloes, Broze GJJ, Miletich JP, Sadler JE. Evolution of human von Willebrand factor: cDNA sequence polymorphisms, repeated domains, and relationship to von Willebrand antigen II. Biochem Biophys Res Commun 1987; 144: 657-65.
60 Shelton BBInloes, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459-65.
61 Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98: 503-17.
62 Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 46: 185-90.
63 Sussman II, Rand JH. Subendothelial deposition of von Willebrand’s factor requires the presence of endothelial cells. J Lab Clin Med 1982; 100: 526-32.
64 Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. Biochemistry 1986; 25: 3171-84.
65 Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980; 19: 401-10.
66 von Willebrand EA. Hereditär Pseudohemofili. Finska Läk Sällsk Handl 1926; 68: 87-112.
67 von Willebrand EA, Jürgens R. Über ein neues vererbbares Blutungsübel: die konstitutionelle Thrombpathie. Dtsch Arch Klin Med 1933; 175: 453-83.
68 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells. Identification of a large precursor polypeptide chain. J Biol Chem 1983; 258: 2065-7.
69 Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 1984; 99: 2123-30.
70 Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol 1986; 102: 1320-4.
71 Wahlbert TB, Blombäck M, Ruggeri ZM. Differences between heterozygous dominant and recessive von Willebrand’s disease type I expressed by bleeding symptoms and combinations of factor VIII variables. Thromb Haemost 1983; 50: 864-8.
72 Ware J, Dent JA, Azuma H, Sugimoto M, Kyrle PA, Yoshioka A, Ruggeri ZM. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane Glycoprotein IB-IX receptor. Proc Natl Acad Sci USA 1991; 88: 2946-50.
73 Zhang ZP, Lindstedt M, Falk G, Blombäck M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 1992; 51: 850-8.
74 Zhang ZP, Falk G, Blombäck M, Egberg N, Anvret M. A single cytosine deletion in exon 18 of the von Willebrand factor gene is the most common mutation in Swedish vWD type III patients. Hum Mol Genet 1992; 01: 757-8.
75 Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand’s disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest 1971; 50: 244-54.
76 Zucker MB, Broekman MJ, Kaplan KL. Factor VUI-related antigen in human blood platelets. Localization and release by thrombin and collagen. J Lab Clin Med 1979; 94: 675-82.